Prot #C-700-01: A Phase 1/2, Open-Label, Multiple Ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN2034 in Subjects With Metastatic or Locally Advanced Solid Tumors, With Expansion to

Project: Research project

Project Details

StatusActive
Effective start/end date9/29/17 → 9/29/23

Funding

  • Agenus Inc. (Prot #C-700-01)